M
Manish Gupta
Researcher at Bristol-Myers Squibb
Publications - 41
Citations - 1244
Manish Gupta is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Population. The author has an hindex of 15, co-authored 38 publications receiving 998 citations. Previous affiliations of Manish Gupta include University of Tennessee Health Science Center & Children's Hospital of Philadelphia.
Papers
More filters
Journal ArticleDOI
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors.
TL;DR: A full covariate model was developed to assess covariate effects on pharmacokinetic parameters and found that sex, PS, baseline eGFR, age, race, baseline lactate dehydrogenase, mild hepatic impairment, tumor type, tumor burden, and programmed death ligand‐1 expression had a significant but not clinically relevant (<20%) effect on nivolumab clearance.
Journal ArticleDOI
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
TL;DR: The major characteristics of the pharmacokinetic profile of all 3 PDE5 inhibitors, including bioavailability and rate of absorption, Biopharmaceutical Classification System categorization, elimination mechanisms, and metabolic profile including active metabolites are discussed.
Journal ArticleDOI
The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy
TL;DR: A critical assessment of the pharmacokinetics of PDE5 inhibitors is provided, which may assist clinicians in tailoring drug and/or treatment regimens to the unique needs of each individual patient with erectile dysfunction.
Journal ArticleDOI
Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy
TL;DR: The scientific overview of cancer immunotherapy, mechanisms of the inhibitors, clinical pharmacology considerations, advances in combination therapies, and challenges in drug development are discussed.
Journal ArticleDOI
Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
Jennifer Sheng,Shivani Srivastava,Kinjal Sanghavi,Zheng Lu,Brian J. Schmidt,Akintunde Bello,Manish Gupta +6 more
TL;DR: The ability of immuno‐oncology to meet its full potential will depend on overcoming development challenges, including the need for clear strategies to determine optimal dose and scheduling for monotherapy as well as combination approaches.